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ABSTRACT
Objectives: Endocrine therapy is the recommended systemic treatment for steroid receptor positive endometrial stromal 
sarcoma (ESS). There is no current consensus on the optimal hormonal therapy for ESS. The literature offers several reports 
on advanced/recurrent/metastatic ESS patients treated with progestins, whereas data on the efficacy of aromatase inhibi-
tors are scarce. 
Material and methods: We retrospectively identified cases treated for ESS with aromatase inhibitors at our institutions. There 
were five patients with advanced or unresectable recurrent estrogen, progesterone and androgen receptor-positive ESS, 
treated with aromatase inhibitors: letrozole or anastrozole (at a daily dose of 2.5 mg and 1 mg, respectively), as first-line 
endocrine therapy in all but one case treated following progression with megestrol acetate.
Results: Disease stabilization was achieved in four cases (80%), including two with long-term progression-free survival 
for up to 10 years attained under letrozole treatment, and one case after prior progestin treatment. During therapy, no 
substantial toxicity was observed.
Conclusions: Aromatase inhibitors as first- or second-line endocrine treatment achieve disease control in most steroid 
receptor positive ESS. Our series of cases is evidence of aromatase inhibitors efficacy as long-term endocrine treatment 
option for ESS patients.
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INTRODUCTION
Endometrial stromal tumors are rare entities, comprising 
approximately < 1% of all uterine malignancies. Currently, 
malignant stromal tumors are subdivided into endometrial 
stromal sarcoma (ESS — previously known as low-grade 
endometrial stromal sarcoma) and high-grade/undifferen-
tiated forms, which are distinguished by clinical behavior, 
histologic appearance, immunohistochemical features and 
chromosomal translocations [1, 2]. CD10 was the most com-
monly used immunohistochemistry marker for ESS. Unlike 
non-ESS, a highly aggressive sarcoma with poor progno-
sis, ESS is generally a slow-growing malignancy with good 
prognosis, with an indolent clinical course, but with a high 
tendency for late recurrences. Advanced age and increased 
tumor size were found to be associated with decreased 
survival in large retrospective cohort of ESS [3]. Almost 80% 
of ESS express estrogen (ER) and progesterone receptors 
(PgR). Moreover, in most cases of ESS, the intratumoral im-
munohistochemical expression of gonadotropin releasing 
hormone receptor (GnRH-R) as well as androgen receptor 
(AR) and aromatase was demonstrated [4, 5]. The predictive 
value of these markers has not been determined to date. As 
far as steroid receptor positive tumors are concerned, hor-
monal therapy, mainly with progestins, has been shown to 
be an effective treatment for advanced ESS, which improves 
long-term survival.
Objectives
There is no current consensus on the optimal hormonal 
therapy for ESS. Due to the rarity of this tumor, no large-scale 
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cohort studies or prospective studies regarding endocrine 
treatment have been conducted, with most of the available 
reports being case reports and small series. We present 
two-center experience with aromatase inhibitors (AIs) for 
ESS, based also on a small study group.
MATERIAL AND METHODS
A retrospective search of all patients treated with AIs for 
ESS was undertaken. A total of 5 consecutive patients with 
unresectable pelvic/abdominal steroid receptor positive 
ESS treated with AIs in two centers since 2007 were identi-
fied (Tab. 1). Letrozole (4 patients) and anastrozole were 
administered at the standard daily dose of 2.5 mg and 1 mg, 
respectively. Three patients, including two with late recur-
rent disease, underwent exploratory re-laparotomy, and 
two, with residual ESS, were treated postoperatively. Two 
patients with recurrence were previously misdiagnosed as 
having benign conditions. AIs were administered as first-line 
endocrine therapy in all but one case with local progression 
after two years of megestrol acetate therapy.
Treatment response was assessed by the pelvis and 
abdomen computerized tomography (CT) performed every 
3–6 months (sometimes less often). Tumor response was 
determined using RECIST criteria.
RESULTS
Disease stabilization with both AIs was achieved in four 
cases (80%) and, based on repeated control pelvis and abdo-
men CT imaging, it lasts till now. All patients were alive at the 
time this manuscript was written. The progressed patient is 
administered chemotherapy, and is alive, 11 months since 
the beginning of AI therapy. During treatment with AIs, 
no significant side effects were observed. Three patients 
complained about mild (Grade 2) myalgia (3 patients) and 
hot flashes (Grade 1 and 2) (2 patients). Nonetheless, all 
patients are in excellent general condition. Notably, two 
women including the oldest patient (case 2. and 5.) have 
got painless pelvic bone involvement.
Two patients (case 1. and 2.) got osteopenia at the be-
ginning of the AI therapy. Bone mineral density testing 
was performed annually. Case 1, already receiving standard 
osteoporosis prophylaxis, presented bone density loss after 
three years of letrozole therapy initiation and was diagnosed 
with osteoporosis. Therefore, bifosfonate (alendronate) was 
added to vitamin D3 and calcium supplementation.
DISCUSSION
Approximately 40–50% of patients with ESS of the uterus 
develop recurrent disease, which typically presents as pelvis, 
abdomen or lung metastases. Ovarian preservation and high 
levels of proliferation, as measured by the Mitotic Activity 
Index, in ESS tumors defined according to the 2003 WHO 
criteria, were found to be predictive of recurrence [6]. Debulk-
ing surgery of recurrence should be considered, if possible. In 
unresectable disease, endocrine therapy is thought to be the 
treatment of choice since ESS is considered to be relatively ra-
dio- and chemo-therapy resistant. Under hormonal therapy, 
partial response (PR) or disease stabilization (SD) of ESS le-
Table 1. Patient characteristics and outcomes
Case
Age at 
primary 
TAH/BSO
[years]
Diagnosis 
after primary 
TAH/BSO
Interval from 
primary 
TAH/BSO to 
recurrence
IHC profile of ESS tissue
Site of 
lesions at 
letrozole 
therapy
Therapy 
(another 
systemic or 
local therapy)
Response/
duration 
[month]
1. 53 Adenosisb 7 y ER +, PR +, AR+, CD10 +, Ki67 & Desmin & ASMA focally +, CD117 –, aromatase -*
Abdomen, 
pelvis Letrozole SD/133 +
2. 30a EndolymphaticStromatosisb 30 y
ER +, PR +, AR +, CK & EMA & CD99 & CD34 & 
Bcl2 +, Desmin & Ki67 focally +, aromatse -*
Abdomen, 
pelvis Letrozole SD/127 +
3. 53 ESS 0
ER +, PR +, AR +, CD10 & WT1 & Wimentin +, 
CD34 & Desmin & SMA & CKAE1/3 & Cyclin D 
focally +, Ki67 20%, CD117 -, aromatase -*
Abdomen, 
pelvis
Anastrozole
(pelvic RT; 
30Gy/10 fraction)
SD/26 +  
4. 63 ESS 1.5 y
ER +, PR +/-, AR +, CD10 +, CD117 & CD34 & 
SMA & EMA & Desmin & S100 & CKAE1/AE3 & 
Synaptofizine - , aromatase -*
Abdomen, 
pelvis Letrozole  PD
5. 37 ESS 0
ER +, PR +, AR +, CD10 & Cyclin D1 & WT1 +, 
CKAE1/3 +/-, CD117 & SMA & Desmin & 
Inhibin & H-caldesmon -, Ki67 20%,  
aromatase -*
Pelvis Letrozole (after megestrol)** SD/15 +
TAH/BSO, total abdominal hysterectomy and bilateral salpingo-oophorectomy; ESS — endometrial stromal sarcoma; IHC — immunohistochemistry; ER — estrogen 
receptor; PR — progesterone receptor; AR — androgen receptor; SD — stable disease;  PD — progressive disease; a — after primary surgery she was not prescribed 
estrogen-containing hormone replacement therapy; b — after re-operation due to pelvic/abdominal mass, the slides from the uteri resected earlier in both patients 
were reviewed and ESS was confirmed in both tumors; *using CYP19/aromatase polyclonal antibody (1: 25 dilution, LS-B3021, LifeSpan BioSciences, Inc.); **megestrol 
as adjuvant therapy was administered due to pT4N1 ESS (bladder infiltration) with R1 resection
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sions were typical, however complete response (CR) was also 
observed. No particular drug, dose, or regimen of endocrine 
treatment in ESS has been found to be superior. Several 
studies have demonstrated long-term benefits of progestins, 
including megestrol acetate and medroxyprogesterone ac-
etate (MPA). Despite abnormal weight gain, hot flashes and 
swelling related to glucocorticoid activity, the side-effects of 
a long-term progestin therapy include increased risk of severe 
depression and thromboembolic complications. Because of 
these side effects, the third generation AIs (letrozole, anastro-
zole and exemestane) have been considered as an alterna-
tive endocrine treatment for ESS. AIs are medications which 
interfere with the aromatase enzyme, which is responsible 
for the conversion of testosterone and androstenedione into 
estrogen, established in endocrine therapy for breast cancer. 
Owing to the rarity of ESS, data on the efficacy of AIs for ESS 
are scarce. PubMed database identified articles with a total of 
approximately 50 cases described in detail since 2001, treated 
with aminoglutethimide, anastrozole, letrozole and exemes-
tane (Tab. 2) [7–24]. AIs were used as first-line or second-line 
(or later-line) treatment, salvage after prior chemotherapy or 
adjuvant therapy after complete resection of the metastatic 
lesions. Clinical benefit (CR + PR + SD), frequently long-term, 
was reported in almost all patients. Under non-steroid AI 
letrozole, the most frequently used compound, objective 
response which lasted from 9 to 124 months, including 12 PR 
and nine CR among 27 cases, was reported [9–11, 19, 20, 23]. 
In the Yamaguchi et al., series of 5 patients, CR with letro-
zole was obtained in two cases with advanced or recurrent 
pelvic/abdomen ESS for 96 and 87 months, SD for 10 and 
46 months also in two subjects, and PR in the remaining 
one patient (with 1 preserved ovary) who received letrozole 
plus GnRH analog and minodronate for lung metastases [23]. 
To the best of our knowledge, this was the only study with 
aromatase expression assessment; in all cases it was greater 
than 80% positive, with moderate intensity. Among our series 
of patients with negative aromatase expression ESS treated 
with non-steroidal AIs, the two cases with late relapsed ESS 
achieved SD with letrozole for more than 10 years. This is 
the longest reported ESS treatment with AIs. Anastrozole 
has shown clinical benefit, most frequently after progestins, 
for hormonally sensitive ESS tumors [7, 8, 18, 22]. In another 
study which included patients with metastatic ESS, positive 
outcomes with non-steroidal AIs (letrozole or anastrozole) 
in both, first- (11 cases) and second- (7 cases) line treatment 
was demonstrated [25]. The authors stated that all available 
hormonal options should be used in sequence in the man-
agement of ESS. In the anecdotal reports on exemestane, 
a well-tolerated type I steroidal irreversible AI, a prolonged 
response, even in case of progression after prior AI treatment, 
was observed [8, 22].  
Based on different mechanisms of action and the lack of 
cross-resistance between different AIs, hormonal manipula-
tions including continuing different AI therapy despite the 
failure of prior AI, or the addition of GnRH analogues to AI 
in ESS tumors that are ER+ seems to be justified. Moreover, 
the use of GnRH analogues alone or in combination with 
MPA, as well as a single modality treatment with progestins 
or antiandrogen therapy, seems valid. Chemotherapy should 
be limited to patients with hormone-unresponsive tumors. 
Good tolerance of AIs was reported in all abovemen-
tioned studies. Nevertheless, beside adverse events such 
as myalgia and arthralgia, the long-term use of this class of 
medications results in postmenopausal vasomotor symp-
toms, vaginal dryness and  osteoporosis.
In this series, besides ER and PR expression, aromatase 
and AR expression were assessed as well. To our knowledge, 
only four previous studies evaluated AR expression in ESS, 
but none assessed aromatase at the same time. The ques-
tion whether aromatase and AR, in addition to the ER and 
PR status, may help guide hormonal ESS therapy needs 
further elucidation.
Our study is not without limitations, chief among them 
a small number of the presented cases. However, the rarity of 
the disease, especially with advanced/recurrent/metastatic 
ESS patients treated with AI therapy, is the reasons why no 
large-scale cohort studies for hormonal treatment may be 
performed.
Table 2. Studies with aromatase inhibitors (AIs) in endometrial stromal sarcoma  
Form of AI N Line
Response
References
CR PR SD PD
Letrozole 17
a
10
1st
2nd
6
3
9
3
1
3
1
1
[9, 10, 11–13, 16, 17, 20, 23, 24]
[8, 10, 14–17, 19, 21, 22]
Anastrozole 7b 2nd 1 1 4 1 [7, 8, 18, 22]
Exemestane 2 2nd4th - 1 1 - [8, 22]
Aminoglutethimide 1 1st 1 - - - [19]
CR — complete response; PR — partial response; SD – stable disease; PD — progressive disease; a — one case was treated with letrozole for 8 months followed by 
anastrozole [9]; b — including one case treated with anastrozole after medroxyprogesterone acetate for 14 years
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CONCLUSIONS
Our results support the efficacy of AIs as first- and sec-
ond-line endocrine treatment for recurrent unresectable 
steroid receptor positive ESS. Based on the currently avail-
able literature and considering the efficacy and the favorable 
toxicity profile, AIs should be recommended as first-line 
hormonal therapies for advanced receptor positive ESS.
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